BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND MYC, c-Myc, 4609, ENSG00000136997 AND Treatment
249 results:

  • 1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
    Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
    Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Identification of spatially-resolved markers of malignant transformation in Intraductal Papillary Mucinous Neoplasms.
    Agostini A; Piro G; Inzani F; Quero G; Esposito A; Caggiano A; Priori L; Larghi A; Alfieri S; Casolino R; Scaglione G; Tondolo V; Cammarota G; Ianiro G; Corbo V; Biankin AV; Tortora G; Carbone C
    Nat Commun; 2024 Mar; 15(1):2764. PubMed ID: 38553466
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. EIF2Ss, a Novel c-myc-Correlated Gene Family, is Associated with Poor Prognosis and Immune Infiltration in pancreatic Adenocarcinoma.
    Cao Z; Jing Y; Cheng C; Wang F; Guan M; Zhang K; Jiao J; Ruan L; Chen Z
    Front Biosci (Landmark Ed); 2024 Mar; 29(3):119. PubMed ID: 38538250
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer.
    Dash S; Ueda T; Komuro A; Honda M; Sugisawa R; Okada H
    Cell Death Dis; 2024 Feb; 15(2):131. PubMed ID: 38346958
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The role of histone H1.2 in pancreatic cancer metastasis and chemoresistance.
    Gu J; Zhang J; Xia R; Wang X; Yang J; Xie F; Zhou Q; Li J; Zhang T; Chen Q; Fan Y; Guo S; Wang H
    Drug Resist Updat; 2024 Mar; 73():101027. PubMed ID: 38290407
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Inhibition of Bromodomain Proteins Enhances Oncolytic HAdVC5 Replication and Efficacy in pancreatic Ductal Adenocarcinoma (PDAC) Models.
    Miao T; Symonds A; Hickman OJ; Wu D; Wang P; Lemoine N; Wang Y; Linardopoulos S; Halldén G
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279262
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Integrative analysis of disulfidptosis and immune microenvironment in hepatocellular carcinoma: a putative model and immunotherapeutic strategies.
    Yang T; Liu J; Liu F; Lei J; Chen S; Ma Z; Ke P; Yang Q; Wen J; He Y; Duan J; Zeng X
    Front Immunol; 2023; 14():1294677. PubMed ID: 38235128
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The radiation- and chemo-sensitizing capacity of diclofenac can be predicted by a decreased lactate metabolism and stress response.
    Schwab M; Dezfouli AB; Khosravi M; Alkotub B; Bauer L; Birgani MJT; Multhoff G
    Radiat Oncol; 2024 Jan; 19(1):7. PubMed ID: 38229111
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1.
    Zhang Z; Song B; Wei H; Liu Y; Zhang W; Yang Y; Sun B
    Drug Resist Updat; 2024 Mar; 73():101040. PubMed ID: 38228036
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Investigation of iso-propylchaetominine anticancer activity on apoptosis, cell cycle and Wnt signaling pathway in different cancer models.
    Karamad V; Sogutlu F; Ozkaya FC; Shademan B; Ebrahim W; El-Neketi M; Avci CB
    Fitoterapia; 2024 Mar; 173():105789. PubMed ID: 38158162
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Tumor suppressive function of IGF2BP1 in gastric cancer through decreasing myc.
    Ding N; Cao G; Wang Z; Xu S; Chen W
    Cancer Sci; 2024 Feb; 115(2):427-438. PubMed ID: 38115228
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.
    Jing X; Luo Z; Wu J; Ye F; Li J; Song Z; Zhang Y; Shi M; Sun H; Fang Y; Jiang Y; Ji X
    Cancer Med; 2023 Dec; 12(24):21905-21919. PubMed ID: 38050871
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/myc signaling and restoring chemosensitivity.
    Zheng Q; Tang J; Aicher A; Bou Kheir T; Sabanovic B; Ananthanarayanan P; Reina C; Chen M; Gu JM; He B; Alcala S; Behrens D; Lawlo RT; Scarpa A; Hidalgo M; Sainz B; Sancho P; Heeschen C
    J Exp Clin Cancer Res; 2023 Nov; 42(1):323. PubMed ID: 38012687
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells.
    Zhang K; Sun T; Li W; Guo Y; Li A; Hsieh M; Wang J; Wu J; Arvanitis L; Raz DJ
    Cell Commun Signal; 2023 Nov; 21(1):319. PubMed ID: 37946202
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-myc signaling pathway by inducing β-catenin ubiquitination in pancreatic cancer.
    Kang HW; Kim JH; Lee DE; Lee YS; Kim MJ; Kim HS; Fang S; Lee BE; Lee KJ; Yoo J; Kim HJ; Park JS
    Cancer Biol Ther; 2023 Dec; 24(1):2272334. PubMed ID: 37917550
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. POH1 facilitates pancreatic carcinogenesis through myc-driven acinar-to-ductal metaplasia and is a potential therapeutic target.
    Jing T; Xu X; Wu C; Wei D; Yuan L; Huang Y; Liu Y; Wang B
    Cancer Lett; 2023 Nov; 577():216444. PubMed ID: 37844756
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma.
    Kinnaman MD; Zaccaria S; Makohon-Moore A; Arnold B; Levine MF; Gundem G; Arango Ossa JE; Glodzik D; Rodríguez-Sánchez MI; Bouvier N; Li S; Stockfisch E; Dunigan M; Cobbs C; Bhanot UK; You D; Mullen K; Melchor JP; Ortiz MV; O'Donohue TJ; Slotkin EK; Wexler LH; Dela Cruz FS; Hameed MR; Glade Bender JL; Tap WD; Meyers PA; Papaemmanuil E; Kung AL; Iacobuzio-Donahue CA
    Cancer Res; 2023 Nov; 83(22):3796-3812. PubMed ID: 37812025
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. myc Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast cancer.
    Doha ZO; Wang X; Calistri NL; Eng J; Daniel CJ; Ternes L; Kim EN; Pelz C; Munks M; Betts C; Kwon S; Bucher E; Li X; Waugh T; Tatarova Z; Blumberg D; Ko A; Kirchberger N; Pietenpol JA; Sanders ME; Langer EM; Dai MS; Mills G; Chin K; Chang YH; Coussens LM; Gray JW; Heiser LM; Sears RC
    Nat Commun; 2023 Sep; 14(1):5665. PubMed ID: 37704631
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Targeted inhibition of mTOR by BML-275 induces mitochondrial-mediated apoptosis and autophagy in prostate cancer.
    Li W; Li D; Ma Q; Chen Y; Hu Z; Bai Y; Xie L
    Eur J Pharmacol; 2023 Oct; 957():176035. PubMed ID: 37657741
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Gemcitabine Inhibits the Progression of pancreatic cancer by Restraining the WTAP/myc Chain in an m6A-Dependent Manner.
    Cao P; Zhang W; Qiu J; Tang Z; Xue X; Feng T
    Cancer Res Treat; 2024 Jan; 56(1):259-271. PubMed ID: 37591781
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 13.